After administration of low dose PAOS or glibenclamide, the levels of ALT (Figure 2G), LDL-C (Figure 2H), TC (Figure 2I), and TG (Figure 2J) were lower by 15.7% or 19.1%, 24.5% or 23.5%, 15.8% or 14.9 and 40.9% or 46.8%, respectively, compared to DM model mice. This evidence concerns the gene GPT and diabetes mellitus.